Neratinib Approaches EU Approval for HER2+ Breast Cancer

June 29, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of neratinib for the extended adjuvant treatment of adult patients with early stage hormone receptor–positive, HER2-overexpressed/amplified breast cancer following postoperative trastuzumab. The European Commission will now review the CHMP recommendation and make a final decision on whether to approve neratinib for use in … (leggi tutto)